Groupe d'Etude en Oncologie du Quebec

Titre	A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination With Tremelimumab ± Lenvatinib Given Concurrently With TACE Compared to TACE Alone in Patients With Locoregional Hepatocellular Carcinoma
Protocole ID	EMERALD-3
ClinicalTrials.gov ID	NCT05301842
Type(s) de cancer	Foie
Phase	Phase III
Type étude	Clinique
Médicament	Durvalumab en association avec tremelimumab ± lenvatinib concomitant avec TACE comparé au TACE seul
Institution	CENTRE UNIVERSITAIRE DE SANTE MCGILL SITE GLEN 1001 boul. Décarie , Montréal, QC, H4A 3J1
Ville	Montréal
Investigateur(trice) principal(e)	Dr Louis-Martin Boucher
Coordonnateur(trice)	Ryan Liu 514-934-1934 poste 34905
Statut	Actif en recrutement
Critètes d'éligibilité	No evidence of extrahepatic disease Disease not amenable to curative surgery or transplantation or curative ablation but disease amenable to TACE Child Pugh score class A Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment Measurable disease by Modified Response Criteria in Solid Tumors (mRECIST) criteria Adequate organ and marrow function
Critètes d'exclusion	History of symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardia arrhythmia History of hepatic encephalopathy Major portal vein thrombosis visible on baseline imaging Uncontrolled arterial hypertension Co-infection with HBV and HDV

Groupe d'étude en oncologie du Québec